دورية أكاديمية

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+cell dose, GVHD and disease response.

التفاصيل البيبلوغرافية
العنوان: Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+cell dose, GVHD and disease response.
المؤلفون: Anderlini, P., Acholonu, S. A., Okoroji, G. -J., Andersson, B. S., Couriel, D. R., de Lima, M. J., Donato, M. L., Khouri, I. F., Giralt, S. A., Ueno, N. T., Champlin, R. E.
المصدر: Bone Marrow Transplantation; Sep2004, Vol. 34 Issue 6, p511-514, 4p
مصطلحات موضوعية: GRAFT versus host disease, TRANSPLANTATION of organs, tissues, etc., IMMUNE system, DRUG therapy, BONE marrow transplantation, DRUGS
مستخلص: Summary:Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, prior salvage chemotherapy was administered. The median CD3+cell dose administered was 77.5×106/kg (range 5-285). GVHD developed in all but one patient. The response rate was 4/9 (44%). Three of these four responders developed GVHD and 3/4 had received chemotherapy. No correlation was observed between CD3+cell dose infused and disease response. At the latest follow-up, three patients are alive and six have expired (PD n=3, nonrelapse mortality n=3). The median response duration was 7 months (range 4-9), with one response currently ongoing. These data suggest that DLIs for immunotherapy of recurrent HL have significant activity, although they frequently leads to GVHD. The small sample size does not allow any conclusion as to whether chemotherapy administration increases the chance of response. The CD3 cell dose infused does not seem to correlate with disease response.Bone Marrow Transplantation (2004) 34, 511-514. doi:10.1038/sj.bmt.1704621 Published online 26 July 2004 [ABSTRACT FROM AUTHOR]
Copyright of Bone Marrow Transplantation is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:02683369
DOI:10.1038/sj.bmt.1704621